Clinical Trials Logo

Atrial Remodeling clinical trials

View clinical trials related to Atrial Remodeling.

Filter by:

NCT ID: NCT06425822 Recruiting - Atrial Remodeling Clinical Trials

Characterization of Left Atrial Substrate in Patients With Ventricular Arrhythmias

CLASS-VA
Start date: November 8, 2023
Phase:
Study type: Observational

The goal of this observational study is to analyze the characteristics of left atrial electroanatomical maps in patients without a history of atrial fibrillation but with a high clinical risk of developing it, as indicated by the presence of structural heart disease or a CHA2DS2-VASc score ≥ 2 points. The study cohort will be compared to a historical cohort of patients with diagnosed atrial fibrillation in a propensity-matched fashion. The main questions it aims to answer are: - Are the left atrial electroanatomical changes a consequence or a precursor to the development of atrial fibrillation? - Are the left atrial electroanatomical findings different between patients with atrial fibrillation and those at high risk of developing it? - What is the prognostic impact of left atrial pathologic changes in patients without diagnosed atrial fibrillation in terms of cardiovascular outcomes?

NCT ID: NCT05635864 Recruiting - Stroke Clinical Trials

Impact of Catheter Ablation on ABC Risk Scores

CathonABC
Start date: June 3, 2021
Phase:
Study type: Observational

The aim of this prospective, monocentric, non-randomized trial is to investigate the impact of catheter ablation of atrial tachyarrhythmias on the ABC-stroke and ABC-bleeding risk scores. Participants planned for first catheter ablation for symptomatic atrial tachyarrrhythmias (atrial fibrillation, atrial flutter) will be enrolled. Serial blood samples will be collected before and 3, 6 and 12 months after catheter ablation to calculate the ABC scores as well as the traditional bleeding and stroke risks. Following catheter ablation, continuous rhythm monitoring will be achieved using an insertable monitor or an implanted atrial lead of a cardiac implantable electronic device. Additionally, heart rate monitoring via photoplethysmography using a smartwatch and/or smartphone is performed for a period of six months. Data are analyzed for differences in ABC scores before and after ablation in relation to possible AF/AT recurrences. Furthermore, we are going to compare the sensitivity and specificity of different follow-up modalities post ablation. The monitoring via ICM (gold standard) is compared to smartwatch-based monitoring alone, versus smartphone-based monitoring alone or a combination of both for AT/AF recurrences.

NCT ID: NCT05179616 Recruiting - Clinical trials for Tricuspid Regurgitation

Pforzheim Tricuspid Valve Registry - Outcomes of Percutaneous Tricuspid Valve Repair

Start date: November 30, 2020
Phase:
Study type: Observational [Patient Registry]

The Pforzheim Tricuspid Valve Registry study is designed to confirm the safety and performance of the TriClip™ device in a contemporary real-world setting in critically ill patients. The observational trial is a prospective, single arm, open-label, single-center, post market registry.

NCT ID: NCT04980898 Recruiting - Leg Ulcer Clinical Trials

Electrostimulation System WoundEL for Leg Ulcers Healing (

ELEXICA
Start date: March 16, 2021
Phase: N/A
Study type: Interventional

Several studies have suggested that the endogenous electric field and its polarity stimulate the proliferation and migration of epithelial cells and therefore promote wound healing. WoundEL® will reproduce the endogenous electrical current to stimulate all the factors contributing to healing. Electrostimulation of wounds, including the WoundEL® device, is a therapy listed but not yet reimbursed in France. The aim of this study is to show that the WoundEL® electrostimulation device is superior to the reference treatments recognized by the HAS.

NCT ID: NCT04707352 Completed - Heart Failure Clinical Trials

Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .

MODA
Start date: February 8, 2021
Phase: Phase 3
Study type: Interventional

Dapagliflozin reduces the risk of de novo heart failure (HF) in diabetics and, recently, it has shown to improve the prognosis of patients with HF and reduced left ventricular ejection fraction (HFrEF), by preventing HF decompensations and cardiovascular death. The benefit showed by dapagliflozin in HFrEF was irrespective of diabetes status and glycemic control, which raises the question of which mechanisms are underlying apart from SGLT2 inhibition. In addition, the impact of dapagliflozin on cardiac remodeling parameters, as assessed by echocardiography and biomarkers, is not well established. In particular, left atrial (LA) remodeling represents a relevant prognostic marker, which has received a greater attention in the last years in the context of new imaging tools. The purpose of this study is to assess the effect of dapagliflozin therapy over a period of 6 months in LA remodeling parameters, including geometry and function, as well as complementary biomarkers in patients with chronic HF regardless left ventricular ejection fraction (LVEF). This protocol will allow for evaluation of improved understanding of the interplay between dapagliflozin and LA function , biomarkers, remodeling and outcomes, and will carefully assess such relationships within important cohorts of subjects, such as those with reduced and preserved LVEF. This protocol will also generate a biorepository of well-handled and carefully considered biomarkers, which will allow a better understanding of dapagliflozin mechanism of action.

NCT ID: NCT04687111 Active, not recruiting - Hypertension Clinical Trials

Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation

PARABLE
Start date: December 16, 2015
Phase: Phase 2
Study type: Interventional

Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure with reduced ejection fraction. In stage C HFpEF, sacubitril-valsartan has also been shown to reduce left atrial volume index measured using echocardiography over a 9 month timeframe. The PARABLE study investigates the hypothesis that sacubitril-valsartan can provide benefits in terms of left atrial structure and function as well as left ventricular structure and function in asymptomatic (stage A/B HFpEF) patients. This is a prospective, randomised, double-blind, double-dummy, phase II study design. The patient population will have hypertension and/or diabetes together with preserved ejection fraction, elevated natriuretic peptide (NP) and abnormal left atrial volume index (LAVI, > 28 mL/m2).

NCT ID: NCT03998956 Not yet recruiting - Atrial Fibrillation Clinical Trials

High-density Mapping-guided bOx Isolation and subsTrate Ablation

HOT
Start date: August 1, 2019
Phase: N/A
Study type: Interventional

This study evaluates the efficacy of high-density mapping guided atrial substrate ablation for persistent atrial fibrillation. 1/5 of the patients with persistent atrial fibrillation undergo pulmonary veins isolation, 2/5 of them pulmonary veins and box isolation while others undergo atrial substrate ablation apart from pulmonary veins and box isolation.

NCT ID: NCT03791723 Not yet recruiting - Atrial Fibrillation Clinical Trials

Effect of ARNI in Patients With Persistent AF and Enlarged Left Atrium After Catheter Ablation

APART-AF
Start date: June 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this clinical randomized trial is to evaluate the efficacy and safety of Sacubitril/Valsartan compared with ARB in improving cardiac remodeling in patients With Enlarged Left Atrium Diameter and Persistent AF.

NCT ID: NCT03751644 Completed - Rheumatic Diseases Clinical Trials

Peripherical Neuromuscular Electrical Stimulation in Systemic Autoimmune Myopathies

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

Systemic autoimmune myopathies are a heterogeneous group of rheumatic diseases with progressive skeletal muscle weakness. The relevance of the peripherical neuromuscular electrical stimulation has never applied in the patients with systemic autoimmune myopathies. Therefore, the main objective of the present prospective, randomized, investigator-blind, placebo-controlled study is to evaluate the safety and efficacy of the application of an acute peripherical neuromuscular electrical stimulation session in patients with systemic autoimmune myopathies.

NCT ID: NCT03322085 Completed - Atrial Fibrillation Clinical Trials

The Influence of Catheter Ablation for Atrial Fibrillation on Atrial Electrical

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

This study explored the influence of radiofrequency catheter ablation and cryoballoon ablation on atrial electrical remodeling in patients with atrial fibrillation,the relationship between atrial electrical remodeling and structural remodeling,and which indicators are associated with atrial recurrence after catheter ablation.